418 related articles for article (PubMed ID: 7513904)
1. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens.
Huang AY; Golumbek P; Ahmadzadeh M; Jaffee E; Pardoll D; Levitsky H
Science; 1994 May; 264(5161):961-5. PubMed ID: 7513904
[TBL] [Abstract][Full Text] [Related]
2. Gene vaccination with naked plasmid DNA: mechanism of CTL priming.
Corr M; Lee DJ; Carson DA; Tighe H
J Exp Med; 1996 Oct; 184(4):1555-60. PubMed ID: 8879229
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumour immune responses.
Huang AY; Golumbek P; Ahmadzadeh M; Jaffee E; Pardoll D; Levitsky H
Ciba Found Symp; 1994; 187():229-40; discussion 240-4. PubMed ID: 7796673
[TBL] [Abstract][Full Text] [Related]
4. Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo?
Huang AY; Bruce AT; Pardoll DM; Levitsky HI
J Exp Med; 1996 Mar; 183(3):769-76. PubMed ID: 8642281
[TBL] [Abstract][Full Text] [Related]
5. Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells.
Doe B; Selby M; Barnett S; Baenziger J; Walker CM
Proc Natl Acad Sci U S A; 1996 Aug; 93(16):8578-83. PubMed ID: 8710913
[TBL] [Abstract][Full Text] [Related]
6. Constitutive macropinocytosis allows TAP-dependent major histocompatibility complex class I presentation of exogenous soluble antigen by bone marrow-derived dendritic cells.
Norbury CC; Chambers BJ; Prescott AR; Ljunggren HG; Watts C
Eur J Immunol; 1997 Jan; 27(1):280-8. PubMed ID: 9022030
[TBL] [Abstract][Full Text] [Related]
7. Priming of cytotoxic T lymphocytes by DNA vaccines: requirement for professional antigen presenting cells and evidence for antigen transfer from myocytes.
Fu TM; Ulmer JB; Caulfield MJ; Deck RR; Friedman A; Wang S; Liu X; Donnelly JJ; Liu MA
Mol Med; 1997 Jun; 3(6):362-71. PubMed ID: 9234241
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response.
Chiodoni C; Paglia P; Stoppacciaro A; Rodolfo M; Parenza M; Colombo MP
J Exp Med; 1999 Jul; 190(1):125-33. PubMed ID: 10429676
[TBL] [Abstract][Full Text] [Related]
9. Quantitating presentation of MHC class I-restricted antigens.
Chen W; Bennink JR; Yewdell JW
Methods Mol Biol; 2001; 156():245-54. PubMed ID: 11068765
[No Abstract] [Full Text] [Related]
10. Tumour-specific CTL response requiring interactions of four different cell types and recognition of MHC class I and class II restricted tumour antigens.
Schirrmacher V; Schild HJ; Gückel B; von Hoegen P
Immunol Cell Biol; 1993 Aug; 71 ( Pt 4)():311-26. PubMed ID: 7901150
[TBL] [Abstract][Full Text] [Related]
11. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo.
Paglia P; Chiodoni C; Rodolfo M; Colombo MP
J Exp Med; 1996 Jan; 183(1):317-22. PubMed ID: 8551239
[TBL] [Abstract][Full Text] [Related]
12. Influence of gene-modified (IL-7, IL-4, and B7) tumor cell vaccines on tumor antigen presentation.
Cayeux S; Richter G; Noffz G; Dörken B; Blankenstein T
J Immunol; 1997 Mar; 158(6):2834-41. PubMed ID: 9058819
[TBL] [Abstract][Full Text] [Related]
13. CD8 T-cell priming upon mRNA vaccination is restricted to bone-marrow-derived antigen-presenting cells and may involve antigen transfer from myocytes.
Lazzaro S; Giovani C; Mangiavacchi S; Magini D; Maione D; Baudner B; Geall AJ; De Gregorio E; D'Oro U; Buonsanti C
Immunology; 2015 Oct; 146(2):312-26. PubMed ID: 26173587
[TBL] [Abstract][Full Text] [Related]
14. Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors, melanoma and sarcoma, that are presented by H-2Kb molecules and recognized by CD8+ tumor-infiltrating lymphocytes.
Itoh T; Storkus WJ; Gorelik E; Lotze MT
J Immunol; 1994 Aug; 153(3):1202-15. PubMed ID: 7517974
[TBL] [Abstract][Full Text] [Related]
15. Identification and characterization of the antigen presenting cell in rat autoimmune myocarditis: evidence of bone marrow derivation and non-requirement for MHC class I compatibility with pathogenic T cells.
Ratcliffe NR; Wegmann KW; Zhao RW; Hickey WF
J Autoimmun; 2000 Nov; 15(3):369-79. PubMed ID: 11040077
[TBL] [Abstract][Full Text] [Related]
16. Granulocyte-macrophage colony-stimulating factor gene transfer to dendritic cells or epidermal cells augments their antigen-presenting function including induction of anti-tumor immunity.
Ozawa H; Ding W; Torii H; Hosoi J; Seiffert K; Campton K; Hackett NR; Topf N; Crystal RG; Granstein RD
J Invest Dermatol; 1999 Dec; 113(6):999-1005. PubMed ID: 10594743
[TBL] [Abstract][Full Text] [Related]
17. A nonclassical MHC class I molecule restricts CTL-mediated rejection of a syngeneic melanoma tumor.
Chiang EY; Stroynowski I
J Immunol; 2004 Oct; 173(7):4394-401. PubMed ID: 15383569
[TBL] [Abstract][Full Text] [Related]
18. Defective presentation of endogenous antigen by a cell line expressing class I molecules.
Hosken NA; Bevan MJ
Science; 1990 Apr; 248(4953):367-70. PubMed ID: 2326647
[TBL] [Abstract][Full Text] [Related]
19. Presentation of exogenous antigen with class I major histocompatibility complex molecules.
Rock KL; Gamble S; Rothstein L
Science; 1990 Aug; 249(4971):918-21. PubMed ID: 2392683
[TBL] [Abstract][Full Text] [Related]
20. Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or "self" antigens induce antitumor immunity in vivo.
Tüting T; DeLeo AB; Lotze MT; Storkus WJ
Eur J Immunol; 1997 Oct; 27(10):2702-7. PubMed ID: 9368629
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
